SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Miller who wrote (2874)5/20/1999 2:35:00 PM
From: j_fir2  Read Replies (3) of 10280
 
There is already at least one (fairly new) SSRI antidepressant, Effexor, that works on those three neurotransmitters (seretonin, dopamine, and norepinephrine). The side effect profile of this new one looks about the same as that of all the other SSRIs.

Any of the newer antidpressants might take market share away from Prozac, for a while at least, until people find out what the real story is by using them over time. Prozac has been around for a good long while now, and I believe is still considered the gold standard of antidepressants.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News